What the FDA's July 2026 peptide vote decided

Short answer · as of Oct 17, 2026

Nothing final. On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six of seven peptides for the 503A bulks list, several by narrow margins. FDA staff had recommended against all seven.

The committee advises; the FDA decides. On October 15, HHS and the FDA sent the White House an interim policy that could let pharmacies compound some of these peptides before any final rule.

The seven peptides and how the committee voted

Vote counts are from the July 23–24 meeting. Abstentions are noted where they were reported.

Recommended by the committee (6) Not recommended (1)

These descriptions summarize published research and FDA briefing materials. They aren't claims that any of these work, and they aren't medical advice.
Compound	What it is, and what it's studied for	July vote	Status
BPC-157	Synthetic peptide modeled on a protein found in gastric juice. FDA reviewed it for ulcerative colitis. Most research is in animals, and FDA reviewers cited limited, underpowered human data.	Recommended 8–6 1 abstention	Under review
KPV	Short fragment of the hormone alpha-MSH. FDA reviewed it for wound healing and inflammatory conditions. Human data is limited.	Recommended 8–6 1 abstention	Under review
TB-500	Synthetic peptide related to thymosin beta-4. FDA reviewed it for wound healing. Most research is in animals.	Recommended 8–6 1 abstention	Under review
MOTS-c	Peptide encoded in mitochondrial DNA. FDA reviewed it for obesity and osteoporosis. Research is early, mostly in cells and animals.	Recommended 7–5 2 abstentions	Under review
Epitalon	Short synthetic peptide studied for aging-related and sleep effects, mostly in small, older studies.	Recommended narrow margin	Under review
Semax	Synthetic peptide developed in Russia and used there for certain neurological conditions. Not approved in the US.	Recommended narrow margin	Under review
Emideltide (DSIP)	Peptide studied for sleep, with weak and inconsistent evidence.	Not recommended 7–6 1 abstention	Not recommended

Why the vote was contested

The committee went against the FDA's own scientists. FDA staff's written reviews recommended against adding all seven peptides, citing short, underpowered studies that weren't enough to judge safety or effectiveness. Trade press covering the meeting reported that a committee overriding staff this way was rare, if not unprecedented.

The committee had just been rebuilt. Before the meeting it had only 3 standing voting members against an authorized 12. On June 29, 2026, the FDA announced at least 8 new members, some with ties to peptide businesses or clinics.

The margins were thin. Most recommendations passed by one or two votes, with abstentions.

The October 15 interim access policy

On Thursday, October 15, 2026, HHS and the FDA sent the White House an “interim access policy” for compounding certain peptides. It's reportedly meant to let pharmacies temporarily compound some of the most popular peptides, including BPC-157.

How it would work

It would reportedly use enforcement discretion. The FDA would signal that it doesn't intend to act against qualifying pharmacies that compound covered peptides, while permanent rules are developed. That's different from adding the peptides to the 503A bulks list, which requires formal rulemaking.

What it wouldn't do

It wouldn't make any peptide FDA-approved. They'd remain unapproved drugs.
It wouldn't override state law on prescribing, supervision, and compounding.
It covers pharmacy compounding, so it wouldn't make research-use-only products legal.

What we don't know yet

Which peptides it covers, what conditions apply, and when it would take effect haven't been made public. Nothing has changed until it's published. We'll update this page when it is.

What happens next, and how long it could take

The committee votes, but the FDA decides. Here's the path from here.

White House review of the interim policy.If it's cleared and published, it could let pharmacies compound covered peptides before any final rule.
The FDA decides whether to move toward listing.It has said it won't finalize anything until it has weighed the committee's input and finished its reviews. Its own staff recommended against all seven, so the outcome isn't a given.
A proposed rule, then public comment.The FDA publishes the proposal in the Federal Register and takes comments.
A final rule.Only then would a peptide be formally on the 503A list.
A second committee meeting.Before the end of February 2027, the committee is scheduled to review five more: GHK-Cu, melanotan II, cathelicidin (LL-37), Dihexa acetate, and PEG-MGF.

On timing, estimates vary a lot. Law firms following the process say notice-and-comment rulemaking commonly takes 8 to 12 months and can run past a year. An interim policy could move faster, but its timing depends on the White House review. Treat any specific date as a guess.

Sources

Get an email when the FDA rules.

One short email when the FDA proposes or finalizes anything on peptide compounding, or when the GLP-1 rules change. Nothing else.